Palvella Therapeutics (PVLA) Share-based Compensation (2014 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Share-based Compensation of $51.6 million for Q1 2026, up 4616.64% year-over-year from $1.1 million in Q1 2025, and up 2376.01% quarter-over-quarter from $2.1 million in Q4 2025.
Palvella Therapeutics (PVLA) Share-based Compensation (2014 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Share-based Compensation for 13 consecutive years, with $51.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 4616.64% year-over-year to $51.6 million; the TTM figure through Mar 2026 stood at $51.6 million (up 2802.14% YoY), while the FY2025 annual figure was $30.1 million, up 183.96% from the prior year.
- Share-based Compensation rose to $51.6 million in Q1 2026 per PVLA's latest filing, from $2.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $51.6 million in Q1 2026 and bottomed at -$2.3 million in Q4 2023.
- Historically, Share-based Compensation has averaged $3.8 million across 5 years, with a median of $974000.0 in 2022.
- Annual changes were most pronounced in 2023 — Share-based Compensation sank 341.83% — and 2026, when it jumped 4616.64%.
- Palvella Therapeutics' Share-based Compensation stood at $949000.0 in 2022, then tumbled by 341.83% to -$2.3 million in 2023, then surged by 111.68% to $268000.0 in 2024, then soared by 677.61% to $2.1 million in 2025, then soared by 2376.01% to $51.6 million in 2026.
- Business Quant data shows PVLA's Share-based Compensation at $51.6 million in Q1 2026, $2.1 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 55.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.20 Mn |
| Jun 30, 2026 | 55.20 Mn |
| Mar 31, 2026 | 51.60 Mn |
| Mar 31, 2026 | 51.60 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 268,000.00 |
| Dec 31, 2024 | 268,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Jun 30, 2024 | 217,000.00 |
| Jun 30, 2024 | 217,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Mar 31, 2024 | 146,000.00 |